(A) Expression of nuclear and cytoplasmic β-catenin and (B) the indicated mRNAs, in MDA-MB-231 tumors from mice treated with 20 mg/kg SR-3029 vs. vehicle daily for 7 days (n=4; *, p=0.05; **, p=0.01; ***, p=0.001). (C) Effects of SR-3029 on tumor Cyclin D1 protein expression at day 7. Right panel shows quantification (n=3; **, p=0.01). (D) Frequency of CSNK1D copy number amplifications in renal papillary cell carcinoma (n=172) and bladder cancer tumors (n=220; TCGA). (E) Correlation of CSNK1D DNA copy number and CK1δ expression in renal papillary cell carcinoma (n=172) and bladder cancer (n=220). (F) −log10 p values showing significant overlap between Wnt/β-catenin pathway genes and CK1δ signature lists (p<0.05, fold change >1.5) for indicated cancer types (red line is threshold of significance, p=0.05).